The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Prevalence of and Risk Factors for Medication Nonadherence in Patients With Schizophrenia: A Comprehensive Review of Recent Literature
Abstract
OBJECTIVE: Nonadherence to prescribed antipsychotic medications places patients with schizophrenia at a greatly increased risk of illness exacerbation and rehospitalization. Identification of risk factors for nonadherence is an initial step toward designing effective interventions. This article reviews recent literature on the prevalence of and risk factors for medication nonadherence in patients with schizophrenia. DATA SOURCES: We searched the MEDLINE/HealthSTAR and PsycINFO databases using combinations of the keywords risk factor(s), adherence, compliance, antipsychotic, neuroleptic, schizophrenia, and psychosis for articles published since 1980 that identified risk factors for medication nonadherence in schizophrenia patients. We included reports that (1) were published in English and (2) specifically examined risk factors for medication nonadherence. Thirty-nine articles met our selection criteria. DATA SYNTHESIS: Among the 10 reports that met a strict set of study inclusion criteria, we found a mean rate of nonadherence of 41.2%; the 5 reports that met a stricter set of inclusion criteria had a mean nonadherence rate of 49.5%. In the 39 articles reviewed, factors most consistently associated with nonadherence included poor insight, negative attitude or subjective response toward medication, previous nonadherence, substance abuse, shorter illness duration, inadequate discharge planning or aftercare environment, and poorer therapeutic alliance. Findings regarding an association between adherence and medication type were inconclusive, although few studies explored this relationship. Other factors such as age, gender, ethnicity, marital status, education level, neurocognitive impairment, severity of psychotic symptoms, severity of medication side effects, higher antipsychotic dose, presence of mood symptoms, route of medication administration, and family involvement were not found to be consistent predictors of nonadherence. Limitations of the published literature are discussed. CONCLUSION: Efforts to improve medication adherence in patients with schizophrenia should target relevant risk factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Disruption of treatment coverage has been associated with symptom relapse and increased risk of hospitalization [5–7].”
From Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview (2021) · cites this paper as [6]
In the citing paper
“Similarly, medication non-adherence is consistently associated with patients behavioral practices (e.g., substance abuse) [14, 74] and also patients’ socio-demographic characteristics (such as educational status, age, gender, and employment) [14, 72].”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [14]
In the citing paper
“In the present systematic review, medication non-adherence is associated with poor functioning of the health system such as lack of psychotherapy, lack of information, long treatment duration with little health personnel follow-up, inadequate discharge planning, increased hospitalizations, poor support and care environment, experiencing access barriers to high-quality care and health care”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [14]
In the citing paper
“This systematic review of factors influencing psychotropic medication non-adherence which is consistent with other systematic reviews [14, 72, 73, 77] has shown that medication adherence is mainly affected by patients’ negative attitude toward their medication, lack of insight, negative health belief, and perceived stigma.”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [14]
In the citing paper
“The present systematic review and meta-analysis finding is consistent with a finding from a comprehensive systematic review on schizophrenia which reported that a mean rate of non-adherence was 41.2%.”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [14]
In the citing paper
“In addition, medication non-adherence is associated with clinical- or medication-related factors [14, 72–74, 77].”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [14]
In the citing paper
“The sub-group analysis indicated that a mean non-adherence rate was 49.5% [14]”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [14]
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
The Health Belief Model: a decade later.
Janz, N. K., & Becker, M. H. (1984) · Health Education Quarterly · doi:10.1177/109019818401100101 · Cited by 8,437
Endicott, J. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770310043002 · Cited by 5,686
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982
Negative Symptoms in Schizophrenia: Definition and Reliability
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070020005 · Cited by 2,247
What is Motivational Interviewing?
Rollnick, S., & Miller, W. R. (1995) · Behavioural and Cognitive Psychotherapy · doi:10.1017/s135246580001643x · Cited by 1,737
Assessment of insight in psychosis
AMADOR, X. F., Strauss, D. H., Yale, S. A., FLAUM, M. M., Endicott, J., & Gorman, J. M. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.6.873 · Cited by 1,100
Hogan, T. P., Awad, A. G., & Eastwood, R. (1983) · Psychological Medicine · doi:10.1017/s0033291700050182 · Cited by 1,032
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,000
Chue, P. S., Prinzo, R., & Binder, C. E. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.852 · Cited by 8
Zongo, F. E., Moisan, J., Grégoire, J., LESAGE, A. D., Dossa, R., & Lauzier, S. (2016) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2016.12.006 · Cited by 8
Samalin, L., de Chazeron, I., Belzeaux-R, R., & Llorca, P. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173267 · Cited by 8
Impact of psychoeducation on compliance of inpatients with first episode psychosis
Karpenko, O. (2020) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro202012006292 · Cited by 8
The impact of pharmacists on medication safety in mental health: A narrative review
Khartabil, N., Haghparast, P., Al‐Chokachi, Z., & Clemens, E. (2023) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1900 · Cited by 8
Hobus, I., Rosema, B., Vorstman, J. A. S., Kas, M. J., Franke, S. K., Boonstra, N., & Sommer, I. E. (2023) · Early Intervention in Psychiatry · doi:10.1111/eip.13477 · Cited by 8
“Indeed, a comprehensive literature review showed that poor therapeutic alliance was associated with non-adherence to antipsychotic medication in patients with schizophrenia (Lacro et al., 2002).”
BackgroundAdherence to Heart Failure Treatment in Patients with Peripartum Cardiomyopathy
Hoevelmann, J., Sliwa, K. S., Schaar, J. M., Briton, O., Böhm, M., Meyer, M. R., & Viljoen, C. A. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14712 · Cited by 8
“21 Moreover, inadequate follow-up or discharge planning further contributes to non-adherence.”
BackgroundDisease Management: Multidimensional Approaches to Incomplete Recovery in Psychosis
Lambert, T. J. R. (2010) · Advances in biological psychiatry · doi:10.1159/000319811 · Cited by 8
Fischel, T., Krivoy, A., Kotlarov, M., Zemishlany, Z., Loebstein, O., Jacoby, H. E., & Weizman, A. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2012.06.005 · Cited by 8
Drug safety evaluation of olanzapine pamoate
Schöttle, D., Kuhnigk, O., & Naber, D. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.832753 · Cited by 8
“There are different factors, that are associated with non-adherence such as lack of or poor insight into one’s illness (as probably being the most important factor), poor patient education, lack of efficacy, negative attitude toward medication, poor therapeutic alliance, comorbid SUD disorders and insufficient planned…”
BackgroundCiudad, A., Bernardo, M., San, Olivares, J. M., Dilla, Polavieja, Gilaberte, & Álvarez (2011) · Patient Preference and Adherence · doi:10.2147/ppa.s26253 · Cited by 8
Deane, F. P., McAlpine, E., Byrne, M. K., Davis, E., & Mortimer, C. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.11.055 · Cited by 8
“Non-adherence in schizophrenia often results in illness exacerbation, relapse, and increased re-hospitalisation (Coombs et al., 2003; Day et al., 2005; Dolder et al., 2003; Kikkert et al., 2008; Lacro et al., 2002; Marland and Cash, 2001; Rettenbacher et al., 2004).”
BackgroundFefeu, M., de Maricourt, P., Cachia, A., Hoertel, N., Vacheron, M.-N., Wehbe, E., Rieu, C., Olié, J., Krebs, M., Raphaël Gaillard, B., et al. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.09.041 · Cited by 8
Perspective on medication decisions following remission from first-episode psychosis
Hui, C. L. M., Lam, B. S. T., Lee, E. H. M., Chan, S. K. W., Chang, W. C., Suen, Y. N., & Chen, E. Y. H. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.02.007 · Cited by 10
Vega, D., Acosta, F. J., & Saavedra, P. (2020) · World Journal of Psychiatry · doi:10.5498/wjp.v10.i11.260 · Cited by 8
Lehti, V., Taipale, H. T., Gissler, M., Tanskanen, A. J., Elonheimo, M., Tiihonen, J., & Suvisaari, J. (2021) · Psychological Medicine · doi:10.1017/s003329172100218x · Cited by 8
Khandker, R. K., Chekani, F., Limone, B. L., & Thiel, E. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03746-0 · Cited by 8
“pharmacy claims paid through insurance and not abandoned or not filled by the patient) [14].”
BackgroundResultMedication adherence in schizophrenia: a comparison between outpatients and relapse cases.
Razali, S. M., & Yusoff, M. Z. A. M. (2014) · PubMed · Cited by 8
Brouwers, F. M., Courteau, J., Grégoire, J., Moisan, J., Lauzier, S., LESAGE, A. D., Fleury, M., & Vanasse, A. (2013) · The Canadian Journal of Psychiatry · doi:10.1177/070674371305800804 · Cited by 8
Costo-efectividad de intervenciones para esquizofrenia en México
Cabello-Rangel, H., Diaz‐Castro, L., & Arredondo, A. (2011) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 8
Misdrahi, D., Delgado, A., Bouju, S., Comet, D., & Chiariny, J.-F. (2013) · L Encéphale · doi:10.1016/j.encep.2012.03.005 · Cited by 8
Social Interaction and Drug Attitude Effectiveness in Patients with Schizophrenia
Tsai, J.-K., Lin, W., & Lung, F. (2011) · Psychiatric Quarterly · doi:10.1007/s11126-011-9177-z · Cited by 8
Present and future of secondary prevention after an acute coronary syndrome
Keller, P., Carballo, S., & Carballo, D. (2011) · The EPMA Journal · doi:10.1007/s13167-011-0129-3 · Cited by 8
Ye, W., Ascher‐Svanum, H., Tanji, Flynn, & Takahashi (2011) · Patient Preference and Adherence · doi:10.2147/ppa.s26002 · Cited by 8
“67 Additionally, insight into illness 67 as well as positive attitudes toward medication 49,68 have been identified as being potentially important in the predictors of antipsychotic persistence.”
Kelin, K. (2010) · Patient Preference and Adherence · doi:10.2147/ppa.s11934 · Cited by 8
“9%) compared with the rates reported in a comprehensive literature review, which showed that nonadherence rates vary from 4% to 72% in patients with schizophrenia.(5) The low nonadherence rate in this study may be a result of physicians’ tendency to overestimate patient adherence to medication,(27,28) as well as the c…”
Adherencia subóptima al tratamiento en la esclerosis múltiple
Perrín, R. S., García-Valdecasas, M. F.-P., Eguizabal, L. A., Pérez, I. G. P., Muñoz, N. M., Barrueta, O. I., & Callejón, G. A. C. (2011) · Farmacia Hospitalaria · doi:10.1016/j.farma.2011.02.006 · Cited by 8
Poor adherence to antipsychotics amongst schizophrenia patients in Nigeria
Enaohwo Meshach, O., King, K. M., & Fulton, J. A. (2013) · International Journal of Culture and Mental Health · doi:10.1080/17542863.2013.783091 · Cited by 8
Attitudes of patients and family members towards implantable psychiatric medication
Dankert, M. E., Brensinger, C. M., Metzger, K. L., Li, C., Koleva, S. G., Mesén, A., LaPrade, B., Wiguna, T., Han, C., Farooq, S., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.05.008 · Cited by 8
“Factors associated with nonadherence included poor insight, negative attitude, substance abuse, inadequate discharge planning/therapeutic alliance (Lacro et al., 2002).”
BackgroundEffiong, J. H., & Umoh, K. A. (2015) · Clinical Medicine and Diagnostics · Cited by 8
Improving Medication Adherence in Alcohol Dependence
Pettinati, H. M. (2006) · The Journal of Clinical Psychiatry · Cited by 8
Métodos de valoración de la adherencia al tratamiento psiquiátrico en la práctica clínica
Cuevas, C. D. L., & Sanz, E. J. (2015) · Revista Iberoamericana de Psicología y Salud · doi:10.1016/j.rips.2015.10.001 · Cited by 8
Law, H., Carter, L., Sellers, R., Emsley, R., Byrne, R. E., Davies, L. M., French, P., Haddad, P. M., Pitt, E., Pyle, M., et al. (2017) · Psychosis · doi:10.1080/17522439.2017.1316302 · Cited by 8
Ethnic and Age Disparities in Patients Taking Long-acting Injectable Atypical Antipsychotics
Soleman, M., Lam, N. H., & Woo, B. K. P. (2017) · Cureus · doi:10.7759/cureus.1772 · Cited by 8
Khorassani, F., Tellier, S., & Tsapepas, D. S. (2018) · Journal of Pharmacy Practice · doi:10.1177/0897190018764074 · Cited by 8
“Social and economic factors such as low socioeconomic status, lack of adequate social support, and low education level may also prevent adherence in the psychiatric population.(7)”
BackgroundTreatment Rate of Schizophrenia in China: a Meta-Analysis of Epidemiological Studies
Qi, H., Zong, Q.-Q., An, F., Zhang, L., Ungvari, G. S., Sim, K., Park, S., & Xiang, Y. (2020) · Psychiatric Quarterly · doi:10.1007/s11126-020-09740-7 · Cited by 8
“, negative symptoms and cognitive deficits), medication-induced side effects (8), poor insight into the illness, substance abuse, stigma and poor treatment adherence (9), treatment rate of schizophrenia ranged from 20% to 56% across studies (10, 11), which is lower compared to most other chronic diseases (12) and is a…”
Satisfaction Survey on Antipsychotic Formulations by Schizophrenia Patients in Japan
Hatano, M., Takeuchi, I., Yamashita, K., Morita, A., Tozawa, K., Sakakibara, T., Hajitsu, G., Hanya, M., Yamada, S., Iwata, N., et al. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.4.610 · Cited by 8
“Medication-related risk factors include high antipsychotic doses, complex medication regimens, and the use of typical antipsychotics [4].”
BackgroundSalem, A., Kushnier, A., Dorio, N. B., & Reeves, R. (2015) · PubMed · Cited by 8
Zarea, K., Moghadam, M. F., & Hakim, A. (2016) · Issues in Mental Health Nursing · doi:10.1080/01612840.2016.1239147 · Cited by 8
“Therefore, the nature and extent of training psychiatric issues along with the desired therapeutic alliance is known as an important factor in improving the medication adherence behavior (Kane et al., 2013; Lacro et al., 2002; Okuno, Yanagi, & Tomura, 2001).”
BackgroundGroup psychoeducation for forensic long-term patients with schizophrenia
Aho‐Mustonen, K. (2011) · UEF eRepo (University of Eastern Finland) · Cited by 8
Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
Bumb, J. M., Enning, F., & Leweke, F. M. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113136660165 · Cited by 7
Pilon, D., Amos, T. B., Germain, G., Lafeuille, M., Lefèbvre, P., & Benson, C. J. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1277989 · Cited by 7
“The remaining 44 states have access to the access and reimbursement (1), care transition support (2), and reminder alerts (3) offerings only.”
BackgroundIasevoli, F., Fagiolini, A. M., Formato, M. V., Prinzivalli, E., Giordano, S., Balletta, R., Luca, V. D., & de Bartolomeis, A. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.01.015 · Cited by 9
Fiore, G., Bertani, D. E., Marchi, M., Cardoso, G., & Galeazzi, G. M. (2021) · Jornal Brasileiro de Psiquiatria · doi:10.1590/0047-2085000000311 · Cited by 7
“(4) Determining how studies are related: identification and extraction phase of the key concepts forming the basis of the single studies.”
BackgroundAli, M. M., Taha, M. M. E., Ahmed, A. E., Ali, S. A., Baiti, M. A., Alhazmi, A. A., Alfaifi, B. A. H., Majrabi, R. Q., Khormi, N. Q. M., Hakami, A., et al. (2023) · Cureus · doi:10.7759/cureus.46118 · Cited by 7
“…ramifications of non-adherence include the need for readmission to medical facilities, reduced quality of life or psychosocial effects, recurrence of symptoms, heightened prevalence of comorbidities, inefficiency in allocating healthcare resources, and an elevated risk of suicide [3,4,15-18].”
BackgroundPersistence in Treatment for One Year Among Patients in Nigeria With First-Episode Schizophrenia
Esan, O. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300294 · Cited by 7
Missed appointments and medication non-compliance among consecutive psychiatric patients
Alpak, G., Aksoy, İ., Demir, B., Ünal, A., Vırıt, O., Bülbül, F., & SAVAS, H. A. (2015) · Journal of Mood Disorders · doi:10.5455/jmood.20151110015147 · Cited by 7
“Family and social support were associated with non-compliance in some studies that we failed to duplicate (10,14,18) but difficulties in the transportation were found to be related to non-compliance similar to our study (10).”
BackgroundResultChui, E., Wong, K. L., Chan, K. Y., & Wong, M. M. C. (2018) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2018.09.005 · Cited by 8
Torrecilla-Olavarrieta, R., Pérez‐Revuelta, J. I., García‐Spínola, E., Martín, Á. L., Mongil-SanJuan, J. M., Rodríguez‐Gómez, C., Moreno, J. M. V., & González‐Sáiz, F. (2020) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2020.1804942 · Cited by 7
“As other authors have previously suggested (Lacro et al. 2002; McCabe et al. 2012), the relationship between therapeutic alliance and adherence to antipsychotic treatment may be mediated by satisfaction with the medication.”
BackgroundKretchy, I. A., Appiah, B., Agyabeng, K., Kwarteng, E. B., Ganyaglo, E., & Aboagye, G. O. (2021) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-021-01264-9 · Cited by 7
Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN)
Ifteni, P. I., Petric, P. S., & Teodorescu, A. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.767756 · Cited by 7
“), antipsychotic treatment (route of administration, number of administrations and side effects) (11).”
BackgroundMethodCristarella, T., Castillon, G., Nepveu, J.-F., & Moride, Y. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.915 · Cited by 7
Ioasa‐Martin, I., & Moore, L. J. (2012) · International Journal of Mental Health Nursing · doi:10.1111/j.1447-0349.2011.00801.x · Cited by 7
“Several meta-analyses studies show that non-adherence is a complex behaviour affected by a wide variety of factors involving the individual, the environment, and the availability of health-care services (Happell et al. 2002; Lacro et al. 2002; Miller et al. 1997; Zygmunt et al. 2002).”
BackgroundStanković, Ž., & Ille, T. (2013) · Vojnosanitetski pregled · doi:10.2298/vsp1303267s · Cited by 7
Outcomes from a regular medication information programme for consumers with a mental illness
Tran, N., & Castle, D. J. (2012) · Australasian Psychiatry · doi:10.1177/1039856211432478 · Cited by 7
Selecting Patients for Long-acting Novel Antipsychotic Therapy
Lambert, T. J. R. (2006) · Australasian Psychiatry · doi:10.1080/j.1440-1665.2006.02243.x · Cited by 7
Strutton, D. R., Gutiérrez, B., & Blanchette, C. M. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp060635 · Cited by 7
Early Medication Adherence and Insight Change in First-Episode Psychosis
Lepage, M., Bodnar, M. D., Buchy, L., Joober, R., & MALLA, A. K. (2010) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.3.4.2 · Cited by 7
Fluorescence of neutrophil granulocytes as a biomarker for clozapine use
Man, W. H., ten Berg, M. J., Wilting, I., Huisman, A., Cahn, W., Douma, J. W., den Breeijen, H., Heerdink, E. R., Egberts, T. C. G., & van Solinge, W. W. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.08.005 · Cited by 7
“An estimated 25% of the patients is nonadherent within the first 7–10 days of treatment (Keith and Kane, 2003) and studies estimate the mean overall prevalence of non-adherence between 40% and 50% (Lacro et al., 2002).”
BackgroundPharmakotherapie bei Schizophrenie und komorbider Substanzstörung
Wobrock, T., D’Amelio, R., & Falkai, P. (2007) · Der Nervenarzt · doi:10.1007/s00115-007-2310-4 · Cited by 7
Kasper, S. F., Saya, L., Tekin, B., & Loze, J.-Y. (2009) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651500903359861 · Cited by 7
Man, W. H., Pérez‐Pitarch, A., Wilting, I., Heerdink, E. R., van Solinge, W. W., Egberts, T. C. G., & Huitema, A. D. R. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13546 · Cited by 7
Cuevas, C. D. L., Motuca, M., Baptista, T., Tezanos, A. G. V., & de León, J. (2019) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2688 · Cited by 7
Positive Airway Pressure Adherence in Patients with Obstructive Sleep Apnea with Schizophrenia
Saoud, M., Saeed, M., Patel, S. K., & Mador, M. J. (2019) · Lung · doi:10.1007/s00408-019-00302-8 · Cited by 7
Guitter, M., Laprévote, V., Lală, A., Sturzu, L. M., Dobre, D., & Schwan, R. (2020) · Early Intervention in Psychiatry · doi:10.1111/eip.13093 · Cited by 8
Jin, X., Xu, N., Wang, X., Songfan, L. I., Yu, Q., Liang, M., Nan, F., Shu, S., Yan, R., Zhu, Y., et al. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.954 · Cited by 7
Detecting Serious Mental Illness Among Substance Abusers
Swartz, J. A., & Lurigio, A. J. (2005) · Journal of Evidence-Based Social Work · doi:10.1300/j394v02n01_07 · Cited by 7
Dilokthornsakul, P., Thoopputra, T., Pattanaprateep, O., Kongsakon, R., & Chaiyakunapruk, N. (2016) · SAGE Open Medicine · doi:10.1177/2050312116637026 · Cited by 7
“xx) from April 2011 through September 2011; (2) aged 18–65 years; (3) no history of receiving any antipsychotics within six months before the first schizophrenia-related diagnosis; and (4) received antipsychotics at least two times within 6 months after the index date.”
BackgroundCardoso, A. M., Byrne, M. K., & Xavier, M. (2016) · Revista Portuguesa de Saúde Pública · doi:10.1016/j.rpsp.2016.05.004 · Cited by 7
Brilaroxazine (RP5063) Clinical Experience in Schizophrenia: "A New Option to Address Unmet Needs"
Bhat, L., Cantillon, M., & Ings, R. M. J. (2018) · Journal of Neurology and Neuromedicine · doi:10.29245/2572.942x/2018/5.1225 · Cited by 7
Long-Acting Injectable Risperidone: An Emerging Tool in Schizophrenia Treatment
Jarboe, K. S., Littrell, K. H., & Tugrul, K. C. (2005) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20051201-04 · Cited by 7
Pei, X. M., Du, X., Liu, D., Li, X., & Wu, Y. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-087312 · Cited by 6
“Our focus on individualised prediction underscores our commitment Open access to precision medicine, has the potential to revolu-tionise the prognosis of patients with psychotic disorders.”
Christensen, J. F. M. M., Düring, S. W., & Jűrgens, G. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70062 · Cited by 6
Beyond dopamine: Exploring anti-inflammatory mechanisms of antipsychotics
Šafářová, N., Kolenič, M., & Španiel, F. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111459 · Cited by 7
Okada, Y., Inada, K., & Akazawa, M. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.01.019 · Cited by 9
Caballero, J., Xu, J., Hall, D. B., Chen, X., & Young, H. N. (2023) · Mental Health Clinician · doi:10.9740/mhc.2023.08.183 · Cited by 6
“8 Long-acting injectable (LAI) antipsychotic development and use has increased over the past several years.”
BackgroundBrunette, M. F., Roth, R. M., Trask, C. L., Khokhar, J. Y., Ford, J., Park, S. H., Hickey, S. M., Zeffiro, T. A., & Xie, H. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae097 · Cited by 6
Alemu, W. G., Mwanri, L., Due, C., Azale, T., & Ziersch, A. M. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1471297 · Cited by 8
Insight Development in Schizophrenia
Nordick, W. G., & van Heugten, K. (2014) · Qualitative Health Research · doi:10.1177/1049732314529023 · Cited by 6
de Sousa, W. J. F. N., Guimarães, N. S., Viana, C. C., Machado, P. T. S., Medeiros, A. F., Vianna, M. S., de Souza, R. P., Bertollo, C. M., & Martins, M. A. P. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15437 · Cited by 6
Shakeri, A., Chu, C., Stamenova, V., Fang, J., Barker, L. C., Vigod, S. N., Bhatia, R. S., & Tadrous, M. (2022) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgac046 · Cited by 6
Hu, X.-J., Pan, L., & Li, W. (2022) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/155802 · Cited by 7
Marún, F. N., Lew, J. C. H., Cano, J. F., Cardeño, C. A., Lizarazo, J. M. G., Vargas, K. J., Acosta, C. A. P., Gaviria, B. A., & Valencia, J. G. (2008) · Revista Colombiana de Psiquiatría · Cited by 6
Kim, J. E., Moon, J. J., Kim, M. H., Kim, W. J., Park, M. K., Song, T.-H., & Shim, J. C. (2010) · 대한정신약물학회지 · Cited by 6
Chang, C., Tzeng, D., & Lung, F. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2009.11.005 · Cited by 6
Recovery from Schizophrenia: A Four-year Study of an Inner City Cohort
Economou, M. P., Palli, A., Peppou, L. Ε., & Madianos, M. G. (2011) · Community Mental Health Journal · doi:10.1007/s10597-011-9390-0 · Cited by 6
“…explanation for this failure is patients’ high rates of non-adherence to antipsychotic agents, ranging from 20 to 89% (Lieberman et al. 2005; Gilmer et al. 2004; Lacro et al. 2002) with serious consequences on the course of illness such as relapse and hospital admission (Valenstein et al. 2002).”
BackgroundDunn, K. E., King, V. L., & Brooner, R. K. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.01.016 · Cited by 6
“, 2009), and illicit drug use has been associated with poor medication adherence (Keck et al., 1997; Olfson et al., 2000; Magura et al., 2002; Lacro et al., 2002; Weiss, 2004).”
BackgroundBoredom, dopamine, and the thrill of psychosis: psychiatry in a new key.
Branković, S. (2015) · PubMed · Cited by 7
Siegel, S. J., Dankert, M. E., & Phillips, J. M. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50058-5 · Cited by 6
Studying medication adherence in patients with schizophrenia
Sultan, M. A.-R., Hashem, R. E. S., Mohsen, N., Barakat, D. H., Ryad, R. A., & Khalil, A. H. (2016) · Middle East Current Psychiatry · doi:10.1097/01.xme.0000475315.51718.d6 · Cited by 6
Comparison of Paliperidone Palmitate and Risperidone Long-Acting Injection in Schizophrenic Patients
Limosin, F., Belhadi, D., Comet, D., Pacou, M., Bouju, S., Impe, K. V., & Guillon, P. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000827 · Cited by 7
La réhospitalisation en psychiatrie. Facteurs individuels, facteurs organisationnels
Plancke, L., Amariei, A., Flament, C., & Dumesnil, C. (2018) · Santé Publique · doi:10.3917/spub.176.0829 · Cited by 6
Schoemaker, J. H., Vingerhoets, A. J. J. M., & Emsley, R. A. (2018) · CNS Spectrums · doi:10.1017/s109285291700044x · Cited by 6
Lequimener, V., Chirio-Espitalier, M., & Grall‐Bronnec, M. (2018) · L Encéphale · doi:10.1016/j.encep.2018.04.001 · Cited by 6
Drug Attitude Inventory In Bipolar I Patients: Psychometric Properties
Shariati, B., Shabani, A., Kia, E. A., Ahmadzad-Asl, M., Alavi, K., Behbahani, Z. M., Ghasemzadeh, M. R., Hasani, S., Ghiasi, Z., Nasab, F. K., et al. (2018) · Iranian Journal of Psychiatry and Behavioral Sciences · doi:10.5812/ijpbs.9831 · Cited by 7
Merritt, K., Catalán, A., Cowley, S., Demjaha, A., Taylor, M. J., McGuire, P. K., Cooper, R. E., & Morrison, P. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120922967 · Cited by 6
Religiosity and treatment adherence among out-patients with schizophrenia
Amadi, K. U., Aguocha, C., Attama, M. C., Onu, J. U., Odinka, P. C., Nduanya, C. U., Muomah, R. C., & Ndukuba, A. C. (2021) · Mental Health Religion & Culture · doi:10.1080/13674676.2020.1826916 · Cited by 6
“Researchers have concluded that non-adherence may be a greater issue in psychiatry than in general medicine (Cramer & Rosenheck, 1998; Lacro et al., 2002).”
BackgroundDoes religiosity in persons with schizophrenia influence medication adherence
Davuluri, T., Grover, S., & Chakrabarti, S. (2021) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_413_20 · Cited by 6
Sathienluckana, T., Tiangpattanawong, P., Chaiyasukthananoan, K., Jittayanan, P., Sawetwangsing, H., & Puchsaka, P. (2021) · Schizophrenia Research and Treatment · doi:10.1155/2021/8403986 · Cited by 6
“However, nonadherence to oral antipsychotics is a major and serious problem, which is found in 40–50% of patients with schizophrenia [3].”
BackgroundZhao, J., Ou, J., Xue, H. B., Montgomery, W., Liu, L., & Treuer, T. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s39055 · Cited by 6
Ali, A., Carré, A., Orri, M., Urbach, M., Barry, C., Hassler, C., Falissard, B., Berthoz, S., & Nordon, C. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.10.048 · Cited by 6
“Adherence to medication is known to be affected in schizophrenia patients (Lacro et al., 2002; Lieberman et al., 2005), in particular as a result of neurocognitive impairment (Boyer et al., 2012).”
Metadata
- Authors
- Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V.
- Affiliations
- University of California San Diego (US)
- VA San Diego Healthcare System (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-10-15
- Volume
- 63
- Issue
- 10
- Pages
- 892-909
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2070893229
- Cited by
- 1,383
- References
- 74
- Citations by year
- 2026: 42 · 2025: 29 · 2024: 43 · 2023: 55 · 2022: 59 · 2021: 58 · 2020: 63 · 2019: 52 · 2018: 56 · 2017: 65 · 2016: 80 · 2015: 74 · 2014: 57 · 2013: 103 · 2012: 97
- FWCI
- 18.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r29mh056938-04)
- National Institute of Mental Health (MH49671, R01MH059101, MH-43693, MH56938, MH59101, P30MH049671, MH-19934, T32MH019934)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- medication non-adherence, schizophrenia, antipsychotic drugs, risk factors, prevalence, lack of insight, substance abuse, therapeutic relationship, aftercare planning, hospital readmission
- MeSH terms
- Adult, Ambulatory Care, Factor Analysis, Statistical, Female, Hospitalization, Humans, Male, Probability, Research Design, Risk Factors, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Prevalence, Treatment Refusal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
